Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced the opening of a new 30,000 square foot patient service support center in Henderson, Nevada. The facility increases Paysign’s support capacity fourfold and will bolster the company’s rapidly growing patient affordability business.

The expansion reflects Paysign’s strategic focus on scaling operations to meet rapidly growing demand from pharmaceutical manufacturers seeking more effective patient affordability solutions. This demand is being driven by Paysign’s industry leading innovations, including its Dynamic Business Rules solution, a proprietary technology that sets the company apart in the marketplace. Dynamic Business Rules optimize copay assistance program performance and remove financial barriers to treatment by mitigating the effects of copay maximizer programs that redirect assistance away from patients, bringing significant saving to patients and pharmaceutical manufacturers alike.

This expansion not only allows Paysign to scale traditional support services to meet the rapidly growing demand but also allows Paysign to address the pain points pharmaceutical companies often experience in large-scale copay assistance programs by expanding its offerings to provide dedicated, full-time support specialists for individual programs and clients. These dedicated teams provide specialized patient, physician, and pharmacy support customized to each program’s unique requirements, creating an additional layer of value.

“The remarkable growth we are experiencing is a direct reflection of our unwavering commitment to supporting patients and partners,” said Mark Newcomer, President and CEO of Paysign. “Our mission has always been to remove financial obstacles for patients seeking care. The launch of our expanded support center is a testament to our forward-thinking approach and dedication to innovation, ensuring we deliver not only on today’s needs, but on the promises of tomorrow.”

Paysign’s patient affordability business has become the key growth driver for the company, with revenues increasing 190% year-over-year in the second quarter of 2025. The addition of this new facility marks a significant milestone in the company’s ability to meet rapidly rising demand and maintain high service standards as volumes increase.

About Paysign

Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence, enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers, pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they serve.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250915740220/en/

The expansion reflects Paysign’s strategic focus on scaling operations to meet rapidly growing demand from pharmaceutical manufacturers seeking more effective patient affordability solutions.